Latest News

Latest News

May 21, 2020 — ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients

See the Press Release

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Groundbreaking Immunotechnology, One Connection at a Time.

ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart.

View Our Latest Corporate Presentation
Secondary Image

Discover ADMA Biologics Patented Immunotechnology*

Designed for the Immunocompromised

We manufacture, develop and commercialize specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised at risk for certain infections.

Screen and identify high-titer donors

Screen and identify high-titer donors

Hyperimmune donors with high-titer antibodies to select pathogens are identified.

Tailored compositions

Tailored compositions

Tailored plasma pools are derived from a unique blend of normal source plasma and plasma obtained from the selected donors.

Proprietary testing

Proprietary testing

A proprietary microneutralization assay quantitatively measures titer levels of neutralizing RSV antibodies in plasma donor samples.

*The following patents are applied to ASCENIV™ (immune globulin intravenous, human – slra): 9,107,906 composition 9,714,283 use 9,815,886 methods expiration 2035

Poised for Growth

Poised for Growth

Beyond our present focus on the clinical advancement of ASCENIV™ and the expansion of our plasma facilities, we are considering a number of additional opportunities for growth:

  • Evaluating strategies for potential manufacturing capacity expansion.
  • Exploring additional clinical research and commercial opportunities to address unmet needs for immunocompromised patients.
  • Developing additional plasma-derived products through direct R&D and potential licensing opportunities. These follow-on products may include infectious disease specific intravenous immune globulin (IVIG) product candidates targeting immunocompromised patients as well as transplant patients.
  • ADMA Biologics offers a full suite of CDMO and CMO partnering opportunities.

Fiscal Year 2019 Report

Download Report

Our Diversity Makes Us Stronger

The members of ADMA Biologics' management team come from different disciplines and professional backgrounds, we share a common passion and desire to drive goals that improve the lives of patients.

Meet the ADMA Team